Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Jim Cramer weighs in on Johnson & Johnson's Covid vaccine trial results
08:52am, Saturday, 19'th Nov 2022
Johnson & Johnson said Friday its single-dose coronavirus vaccine was 66% effective overall in protecting against Covid-19. The vaccine, however, appeared to be less potent against other variants.
Experts say J&J vaccine will accelerate vaccination in the U.S.
08:52am, Saturday, 19'th Nov 2022
The J&J Covid-19 vaccine has been shipped to states after the FDA approved it for emergency use authorization. The vaccine has 72 percent efficacy in the U.S. against moderate to severe disease.
JNJ vaccine starts shipping after receiving emergency use authorization
08:51am, Saturday, 19'th Nov 2022
Dr. Aditya Gaur, Director of Clinical Research for Infectious Diseases at St. Jude's Children's Research Hospital, joins Worldwide Exchange to discuss the rollout of the Johnson & Johnson vaccine and
Rutgers' Dr. Rey Panettieri on the Johnson and Johnson vaccine
08:18am, Saturday, 19'th Nov 2022
Dr. Rey Panettieri, Rutgers professor of medicine, joins 'Power Lunch' to discuss the vaccine options out there and the state of the vaccination rollout.
How J&J's Covid vaccine efficacy compares to the other candidates
08:13am, Saturday, 19'th Nov 2022
Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, tweeted his reaction to Johnson & Johnson's coronavirus vaccine trial results. CNBC's Becky
CDC raises new concerns over Johnson & Johnson vaccine
07:34am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell reports on CDC concerns over a neurological disorder associated with the Johnson & Johnson vaccine, and whether Covid-19 booster shots will be needed.
J&J reports positive phase 1/2 Covid vaccine trial results
07:22am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell reports that Johnson & Johnson has seen positive results from its Covid vaccine trial. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Pete Najarian and
Expecting data on J&J vaccine's effectiveness against the delta variant
05:16am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell on the need for masks and booster shots to battle the new Covid delta variant.
Which is a better buy: Target or J&J? #AskHalftime
01:00am, Saturday, 19'th Nov 2022
The "Halftime Report" traders answer viewer questions in #AskHalftime.
Analyst Expects Derisking Required Ahead Of Patent Expiry For This Large Pharma/MedTech Stock
07:54pm, Friday, 18'th Nov 2022 Benzinga
Credit Suisse has initiated coverage on Johnson & Johnson (NYSE: JNJ) with a Neutral rating and a price target of $170.
The analyst says that the company, led by new management underway to transiti
7 Analysts Have This to Say About Johnson & Johnson
07:01pm, Friday, 18'th Nov 2022 Benzinga
Johnson & Johnson (NYSE:JNJ) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
6
0
0
Last 3
Analyst Ratings for Johnson & Johnson
05:01pm, Friday, 18'th Nov 2022 Benzinga
Over the past 3 months, 7 analysts have published their opinion on Johnson & Johnson (NYSE:JNJ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
04:58pm, Friday, 18'th Nov 2022 Benzinga
Upgrades
According to Summit Insights Group, the prior rating for Applied Materials Inc (NASDAQ:AMAT) was changed from Hold to Buy. For the fourth quarter, Applied Materials had an EPS of $2.03, comp
Where Johnson & Johnson Stands With Analysts
04:03pm, Friday, 18'th Nov 2022 Benzinga
Analysts have provided the following ratings for Johnson & Johnson (NYSE:JNJ) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
6
0
0
Why J&J Snack Foods Stock Was Up 11% This Week
08:55am, Friday, 18'th Nov 2022
A solid earnings report had investors feeling more optimistic about the business.
